Future Science Group launches Clinical Investigation
journal
16 Dec 2010
In recognition of the methodology, progress and outcome of
clinical trials, Future Science has announced the launch of the
definitive title Clinical Investigation.
The journal is dedicated to systematic coverage of the
methodology, progress and outcomes of clinical trials. As a
peer-reviewed, monthly publication Clinical Investigation
provides a forum for the rapid publication of original research and
critically reviews the latest developments in medical research, from
Phase I trials through to post-marketing studies and
pharmacoeconomic research.
Clinical Investigation assimilates the wealth of information
resulting from the clinical development of new medicines into
concise yet comprehensive formats. The journal addresses
contemporary issues in clinical drug development and methodology,
and also provides a platform for the rapid publication of new drug
data from human studies.
Coverage spans all therapeutic areas and relates to conventional
small-molecule drugs as well as biotech-derived therapeutic
entities, including vaccines, monoclonal antibodies, antisense, cell
and gene therapies and recombinant proteins. The journal publishes
review articles, original papers, perspectives, commentaries,
meeting reports, news, views and more.
Clinical Investigation provides a systematic program of
peer-reviewed coverage relating to the clinical evaluation of new
and established therapies. The audience for Clinical Investigation
includes clinical investigators, healthcare decision makers,
formulary managers, clinicians, regulatory personnel and medical
affairs professionals.
Prof. E. Michael Lewiecki, Senior Editor, is responsible for the
editorial direction of Clinical Investigation, and supported by a
team of Associate Editors and experts making up the international
Editorial Advisory board.
Senior Editor Lewiecki commented, “Clinical Investigation
is an excellent addition to the Future Science journal collection,
Clinical Investigation fulfils an unmet need in providing critical
review of objectives and outcomes of clinical trials."